ATF3 is a neuron-specific biomarker for spinal cord injury and ischaemic stroke.
Jonathan Z PanZhanqiang WangWei SunPeipei PanWei LiYongtao SunShoulin ChenAmity LinWulin TanLiangliang HeJacob J GreeneVirginia YaoLijun AnRich LiangQifeng LiJessica YuLingyi ZhangNikolaos KyritsisXuan Duong FernandezSara MoncivaisEsmeralda MendozaPamela FungGongming WangXinhuan NiuQihang DuZhaoyang XiaoYuwen ChangPeiyuan LvJ Russell HuieAbel Torres-EspinAdam R FergusonDebra D HemmerleJason F TalbottPhilip R WeinsteinLisa U PascualVineeta SinghAnthony M DiGiorgioRajiv SaigalWilliam D WhetstoneGeoffrey T ManleySanjay S DhallJacqueline C BresnahanMervyn MazeXiangning JiangNeel S SinghalMichael S BeattieHua SuZhonghui GuanPublished in: Clinical and translational medicine (2024)
ATF3 was induced specifically in neurons of the spinal cord or cortex within 1 day after SCI or ischemic stroke, respectively. Serum ATF3 protein levels are elevated in clinical patients within 24 hours after SCI or ischemic stroke. ATF3 exhibits neuroprotective properties, as evidenced by the worse neurological outcomes and larger damage regions observed in Atf3 knockout mice compared to wildtype mice following SCI or ischemic stroke.
Keyphrases
- spinal cord injury
- spinal cord
- endoplasmic reticulum stress
- transcription factor
- neuropathic pain
- atrial fibrillation
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- metabolic syndrome
- diabetic rats
- protein protein
- drug induced
- amino acid
- functional connectivity
- binding protein
- patient reported